This study is the first to investigate the prevalence of HBV-associated hepatitis and HBsAg seroreversion in HBsAg-negative, anti-HBc-positive rheumatic patients undergoing ultra-high dose, GC pulse therapy. This evidence concerns the gene KRT88P and hepatitis A virus infection.